Clinical trial
Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00012259 · Shire, Industry · Completed
Key facts
| NCT number | NCT00012259 |
|---|---|
| Title | Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia |
| Official title | A Phase II Study Of Troxatyl In Patients With CML Blastic Phase Disease |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | troxacitabine |
| Enrollment | 31 |
| Start date | Dec 11, 2000 |
| Primary completion | Mar 27, 2002 |
| Completion | Mar 27, 2002 |
| First posted | Feb 26, 2004 |
| Last update posted | Jun 10, 2021 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: